Stockreport

Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call [Yahoo! Finance]

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF SCLC patients with brain metastases (62% at the 1.6 mg/kg dose) with 17% complete responses, rapid onset of effect and a median time on response of nine months, while sa [Read more]